Cargando…
The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
BACKGROUND AND AIM: Although there are case reports and guideline recommendations that states omalizumab can be used in chronic spontaneous urticaria (CSU) patients during SARS-CoV-2 pandemic, there are scarce studies showing the course of Coronavirus disease 2019 (COVID-19) in CSU patients receivin...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier Masson SAS.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189112/ https://www.ncbi.nlm.nih.gov/pubmed/35721324 http://dx.doi.org/10.1016/j.reval.2022.06.003 |